600829.SS
HPGC Renmintongtai Pharmaceutical Corporation [600829.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600829.SS Stock Summary
Top 600829.SS Correlated Resources
600829.SS
Top 10 Correlated ETFs
600829.SS
Top 10 Correlated Stocks
600829.SS
600829.SS Financial details
Company Rating
Strong Buy
Market Cap
4.27B
Income
234.72M
Revenue
9.34B
Book val./share
4.12
Cash/share
1.93
Dividend
-
Dividend %
-
Employees
3.18K
Optionable
No
Shortable
Yes
Earnings
20 Apr 2021
P/E
18.14
Forward P/E
-
PEG
2.93
P/S
0.47
P/B
1.85
P/C
3.95
P/FCF
22.78
Quick Ratio
0.23
Current Ratio
1.42
Debt / Equity
0.03
LT Debt / Equity
0.03
-
-
EPS (TTM)
0.4
EPS next Y
-
EPS next Q
-
EPS this Y
92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.83%
Revenue last 5Y
3.07%
Revenue Q/Q
16.52%
EPS Q/Q
43.81%
-
-
-
-
SMA20
14.29%
SMA50
33.33%
SMA100
33.33%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
10%
ROC
0.12%
Gross Margin
10%
Oper. Margin
3%
Profit Margin
3%
Payout
-
Shs Outstand
579.89M
Shs Float
120.09M
-
-
-
-
Target Price
-
52W Range
5.08-8.38
52W High
-4.75%
52W Low
+52.4%
RSI
59
Rel Volume
2.95
Avg Volume
12.74M
Volume
37.61M
Perf Week
0.79%
Perf Month
19.62%
Perf Quarter
28.72%
Perf Half Y
23.3%
-
-
-
-
Beta
0.582778
-
-
Volatility
0.14%, 0.54%
Prev Close
-0.13%
Price
7.62
Change
0.53%
600829.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 13.81 | 12.17 | 14.41 | 13.78 | 16.03 | |
| Net income per share | 0.44 | 0.44 | 0.46 | 0.25 | 0.48 | |
| Operating cash flow per share | 0.24 | 0.63 | -0.71 | -0.02 | -0.4 | |
| Free cash flow per share | 0.23 | 0.62 | -0.72 | -0.04 | -0.42 | |
| Cash per share | 0.76 | 0.87 | 0.63 | 0.72 | 1.38 | |
| Book value per share | 2.78 | 2.72 | 3.19 | 3.43 | 3.79 | |
| Tangible book value per share | 2.73 | 2.68 | 3.14 | 3.38 | 3.73 | |
| Share holders equity per share | 2.78 | 2.72 | 3.19 | 3.43 | 3.79 | |
| Interest debt per share | 0.4 | 0.43 | 0.95 | 1.1 | 2.37 | |
| Market cap | 7.1B | 3.33B | 4.14B | 3.36B | 3.43B | |
| Enterprise value | 6.88B | 3.05B | 4.3B | 3.56B | 3.96B | |
| P/E ratio | 27.92 | 12.93 | 15.49 | 23.16 | 12.36 | |
| Price to sales ratio | 0.89 | 0.47 | 0.5 | 0.42 | 0.37 | |
| POCF ratio | 51.03 | 9.1 | -10.06 | -364.82 | -14.71 | |
| PFCF ratio | 53.78 | 9.24 | -9.86 | -145.07 | -13.98 | |
| P/B Ratio | 4.4 | 2.11 | 2.24 | 1.69 | 1.56 | |
| PTB ratio | 4.4 | 2.11 | 2.24 | 1.69 | 1.56 | |
| EV to sales | 0.86 | 0.43 | 0.51 | 0.44 | 0.42 | |
| Enterprise value over EBITDA | 18.26 | 7.64 | 9.9 | 12.91 | 8.41 | |
| EV to operating cash flow | 49.45 | 8.33 | -10.44 | -385.84 | -16.98 | |
| EV to free cash flow | 52.11 | 8.46 | -10.23 | -153.43 | -16.13 | |
| Earnings yield | 0.04 | 0.08 | 0.06 | 0.04 | 0.08 | |
| Free cash flow yield | 0.02 | 0.11 | -0.1 | -0.01 | -0.07 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0.03 | |
| Debt to assets | 0.67 | 0.64 | 0.67 | 0.67 | 0.67 | |
| Net debt to EBITDA | -0.58 | -0.7 | 0.36 | 0.7 | 1.12 | |
| Current ratio | 1.4 | 1.46 | 1.42 | 1.43 | 1.42 | |
| Interest coverage | 50.13 | 14.52 | 16.23 | 8.56 | 7.17 | |
| Income quality | 0.55 | 1.42 | -1.54 | -0.06 | -0.84 | |
| Dividend Yield | 0.04 | 0.09 | 0 | 0 | 0.01 | |
| Payout ratio | 1.17 | 1.16 | 0.05 | 0.03 | 0.13 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.05 | -0.02 | 0.02 | 1.51 | 0.05 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.24 | -0.19 | -0.17 | -0.56 | -0.2 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.24 | 5.22 | 5.75 | 4.39 | 6.38 | |
| ROIC | 0.2 | 0.21 | 0.21 | 0.12 | 0.15 | |
| Return on tangible assets | 0.05 | 0.06 | 0.05 | 0.02 | 0.04 | |
| Graham Net | -4 | -3.28 | -4.76 | -5.21 | -5.5 | |
| Working capital | 1.24B | 1.24B | 1.51B | 1.67B | 1.83B | |
| Tangible asset value | 1.58B | 1.55B | 1.82B | 1.97B | 2.17B | |
| Net current asset value | 1.09B | 1.09B | 1.37B | 1.53B | 1.64B | |
| Invested capital | 0.14 | 0.14 | 0.28 | 0.31 | 0.6 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.56B | 2.38B | 2.64B | 2.67B | 2.57B | |
| Average inventory | 1.03B | 987.74M | 1.13B | 1.12B | 1.11B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 126.17 | 124.1 | 129.38 | 137.56 | 108.72 | |
| Days of inventory on hand | 48.38 | 50.59 | 56.99 | 57.82 | 48.49 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.89 | 2.94 | 2.82 | 2.65 | 3.36 | |
| Inventory turnover | 7.54 | 7.21 | 6.41 | 6.31 | 7.53 | |
| ROE | 0.16 | 0.16 | 0.14 | 0.07 | 0.13 | |
| Capex per share | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.43 | 3.58 | 4.01 | 3.92 | 4.57 | |
| Net income per share | 0.17 | 0.07 | 0.08 | 0.1 | 0.15 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | -0.33 | 0.01 | -0.07 | 0.28 | 0.11 | |
| Cash per share | 0.55 | 1.38 | 1.34 | 2 | 1.93 | |
| Book value per share | 3.72 | 3.79 | 3.87 | 3.97 | 4.12 | |
| Tangible book value per share | 3.67 | 3.74 | 3.82 | 3.92 | 4.07 | |
| Share holders equity per share | 3.72 | 3.79 | 3.87 | 3.97 | 4.12 | |
| Interest debt per share | 1.74 | 2.32 | 2.12 | 2.45 | 2.31 | |
| Market cap | 3.51B | 3.9B | 4.38B | 3.66B | 3.38B | |
| Enterprise value | 4.19B | 4.43B | 4.81B | 3.91B | 3.59B | |
| P/E ratio | 8.97 | 22.73 | 23.71 | 15.32 | 9.82 | |
| Price to sales ratio | 1.37 | 1.88 | 1.88 | 1.61 | 1.27 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | -18.32 | 477.54 | -111.33 | 22.69 | 52.82 | |
| P/B Ratio | 1.63 | 1.77 | 1.95 | 1.59 | 1.41 | |
| PTB ratio | 1.63 | 1.77 | 1.95 | 1.59 | 1.41 | |
| EV to sales | 1.63 | 2.13 | 2.07 | 1.72 | 1.35 | |
| Enterprise value over EBITDA | 30.56 | 64.26 | 63.25 | 42.3 | 30.06 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | -21.85 | 542.09 | -122.41 | 24.23 | 56.16 | |
| Earnings yield | 0.03 | 0.01 | 0.01 | 0.02 | 0.03 | |
| Free cash flow yield | -0.05 | 0 | -0.01 | 0.04 | 0.02 | |
| Debt to equity | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | |
| Debt to assets | 0.67 | 0.67 | 0.67 | 0.67 | 0.68 | |
| Net debt to EBITDA | 4.95 | 7.65 | 5.73 | 2.68 | 1.79 | |
| Current ratio | 1.44 | 1.42 | 1.44 | 1.43 | 1.42 | |
| Interest coverage | 16.51 | 3.29 | 4.7 | 7.34 | 21.23 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.03 | 0.17 | 0.2 | 0.07 | 0.1 | |
| Sales general and administrative to revenue | 0.03 | -0.03 | 0.01 | -0.01 | 0.02 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.76 | 2.51 | 2.63 | 3.03 | 3.71 | |
| ROIC | 0.07 | 0.02 | 0.03 | 0.03 | 0.04 | |
| Return on tangible assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham Net | -6.11 | -5.51 | -5.54 | -5.45 | -5.88 | |
| Working capital | 1.81B | 1.83B | 1.88B | 1.96B | 2.05B | |
| Tangible asset value | 2.13B | 2.17B | 2.22B | 2.28B | 2.36B | |
| Net current asset value | 1.6B | 1.64B | 1.7B | 1.76B | 1.86B | |
| Invested capital | 0.46 | 0.6 | 0.54 | 0.61 | 0.56 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.59B | 2.54B | 2.55B | 2.6B | 2.77B | |
| Average inventory | 877.04M | 975.42M | 887.15M | 845.5M | 912.65M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 101.26 | 121.59 | 106.18 | 113.45 | 110.3 | |
| Days of inventory on hand | 35.63 | 54.23 | 39.32 | 36.9 | 36.67 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.89 | 0.74 | 0.85 | 0.79 | 0.82 | |
| Inventory turnover | 2.53 | 1.66 | 2.29 | 2.44 | 2.45 | |
| ROE | 0.05 | 0.02 | 0.02 | 0.03 | 0.04 | |
| Capex per share | 0 | -0.02 | 0 | -0.01 | 0 |
600829.SS Frequently Asked Questions
What is HPGC Renmintongtai Pharmaceutical Corporation stock symbol ?
HPGC Renmintongtai Pharmaceutical Corporation is a CN stock and trading under the symbol 600829.SS
What is HPGC Renmintongtai Pharmaceutical Corporation stock quote today ?
HPGC Renmintongtai Pharmaceutical Corporation stock price is $7.62 today.
Is HPGC Renmintongtai Pharmaceutical Corporation stock public?
Yes, HPGC Renmintongtai Pharmaceutical Corporation is a publicly traded company.
Company Profile
- Volume Average 12.74M
- Market Capitalization 4.27B
- Employee 3.18K
- Headquarters Harbin,CN
- IPO Date 1994-02-24
-
Website
https://www.hyrmtt.com.cn 
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese medicines, Chinese herbal medicine, chemical preparations, antibiotics, biological products, and biochemical drugs, as well as medical equipment and health products. It also provides logistics services, including warehousing and distribution; and hospital services comprising medical treatment, scientific research, prevention, health care, rehabilitation, blood purification, and renal disease treatment. In addition, the company offers Chinese and Western medicines, Chinese herbal medicines, nourishing health care products, medical equipment, cosmetics, and daily necessities through an e-commerce platform. It operates 319 chain stores in Heilongjiang Province. The company was founded in 1950 and is headquartered in Harbin, China. HPGC Renmintongtai Pharmaceutical Corporation is a subsidiary of Harbin Pharmaceutical Group Co., Ltd.
